سعر لاميكتال 2 مجم 30 قرص 2025

Lamictal 2 mg: lamotrigine 2 mg oral chewable/dispersible tablets, pack of 30, by GlaxoSmithKline (Egypt market); phenyltriazine antiepileptic also used for bipolar I maintenance.

• Epilepsy (adults and adolescents 13+ years): adjunctive or monotherapy of partial and generalised seizures including tonic-clonic seizures; seizures associated with Lennox-Gastaut syndrome.Population: Adults and adolescents aged 13 years and aboveelectronic medicines compendium (emc), UK
• Epilepsy (children 2-12 years): adjunctive treatment of partial and generalised seizures including Lennox-Gastaut seizures; monotherapy of typical absence seizures.Population: Children aged 2 to 12 yearselectronic medicines compendium (emc), UK
• Bipolar I disorder: prevention of depressive episodes in patients who experience predominantly depressive episodes (not for acute treatment of manic or depressive episodes).Population: Adults aged 18 years and aboveelectronic medicines compendium (emc), UK

• Most common (>=5%, adjunctive therapy in adults with epilepsy): dizziness, ataxia, somnolence, headache, diplopia, blurred vision, nausea, vomiting and rash; dizziness, diplopia, ataxia, blurred vision, nausea and vomiting were dose related.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to lamotrigine or to any of the excipients.International label, same formulation · electronic medicines compendium (emc), UK
• Patients who have demonstrated hypersensitivity (e.g. rash, angioedema, acute urticaria, extensive pruritus, mucosal ulceration) to the drug or its ingredients.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: serious rashes including Stevens-Johnson syndrome (about 0.3-0.8% in children 2-17 years, 0.08-0.3% in adults), rarely toxic epidermal necrolysis and rash-related death; risk increased by valproate co-administration, exceeding the initial dose or escalation rate, and HLA-B*1502; most occur within 2-8 weeks; discontinue at the first sign of rash unless clearly not drug-related.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Multiorgan hypersensitivity (DRESS) and organ failure, including hepatic failure, have occurred, some fatal; fever or lymphadenopathy may precede rash; evaluate immediately and discontinue if no alternative cause.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Antiepileptic drugs including lamotrigine increase the risk of suicidal thoughts or behaviour; monitor for emergence or worsening of depression and unusual mood changes.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• ValproateValproate reduces lamotrigine clearance; the lamotrigine dose with valproate is less than half that required without it, and co-administration increases serious rash risk.DailyMed (U.S. National Library of Medicine)
• Estrogen-containing oral contraceptives (ethinylestradiol 30 mcg/levonorgestrel 150 mcg)Decrease lamotrigine concentrations by about 50% and levonorgestrel by 19%; dose adjustment needed.DailyMed (U.S. National Library of Medicine)
• CarbamazepineAddition of carbamazepine decreases lamotrigine concentration by about 40% and may increase carbamazepine epoxide levels.DailyMed (U.S. National Library of Medicine)

• Registries and epidemiological studies have not detected an increased frequency of major congenital malformations with lamotrigine; animal studies showed developmental toxicity at doses below clinical exposure and decreased fetal folate in rats.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Data from more than 12,700 monotherapy-exposed pregnancies do not indicate increased major malformation risk at maintenance doses, but EURAP found a higher rate at >=325 mg/day; use the lowest effective dose, give folic acid when planning and in early pregnancy, and note that levels may fall during pregnancy and rise after birth.International label, same formulation · electronic medicines compendium (emc), UK
• Lamotrigine is present in human milk; infant plasma levels up to about 50% of maternal levels; rash, apnoea, drowsiness, poor sucking and poor weight gain have been reported in breastfed infants; monitor the infant and measure serum levels if toxicity is suspected.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Lamotrigine: Precise mechanism unknown; in animal models lamotrigine inhibits voltage-sensitive sodium channels, stabilising neuronal membranes and modulating presynaptic release of excitatory amino acids (e.g. glutamate).